$613.54
+24.50 (+4.16%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TMO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 observational
Held by 31 tracked-famous managers (Dodge & Cox, PRIMECAP MANAGEMENT CO/CA/, VIKING GLOBAL INVESTORS LP, D1 Capital Partners L.P., BAILLIE GIFFORD & CO, +26 more) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: 1 congress / 4 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Project STARFISH - PRJ0002679NCT05727202observationalPrimary Endpoint | — | Completed | Diagnostic test: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel | SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection | 1,909 | 2024-04-02actual | 2024-04-30 |
| Butterfly - Clinical Performance StudyNCT05800158observationalClinical performance evaluation of the COVID-19 test | — | Completed | Diagnostic test: Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit | COVID-19, Coronavirus Infections | 1,076 | 2023-08-10actual | 2023-10-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19